You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Medscape Onsite: Prostate and Bladder Cancer Updates From the Annual American Genitourinary Meeting

  1. Which line of treatment was the IMvigor130 phase 3 study of atezolizumab plus platinum/gemcitabine vs placebo plus platinum/gemcitabine in patients with metastatic urothelial carcinoma (mUC) evaluated in?
    No prior systemic therapy in metastatic setting
    Received at least 1 prior systemic therapy in the metastatic setting
    Received at least 2 or more systemic therapies in the locally advanced setting
  2. The ARAMIS rollover study evaluated the long-term safety and tolerability of darolutamide in patients with non-metastatic castration-resistant prostate cancer? What was the main finding of this study?
    There were several new safety concerns or patients on long term treatment with darolutamide
    About 10% of patients randomized to receive darolutamide in ARAMIS remained on treatment for ≥ 4 years
    Clinical benefit and favorable safety profile of darolutamide in nmCRPC is maintained for several years in some patients